IDEXX Laboratories (IDXX)

The sleeper story is that IDEXX's two quietest numbers this quarter both point the wrong way: installed base growth decelerated to +11% YoY from +12%, and management dropped last quarter's explicit claim of 'modest improvement in our sector outlook' in favor of a pure execution-momentum narrative, while holding the second-half visit guide flat at -1.5% despite beating it in Q2. The obvious headline, another beat-and-raise with 35% reported operating margin, is real, but the $5M net guidance raise reflects $20M of operational improvement less a $15M FX headwind, not a step-change in conviction. The binding constraint isn't demand for diagnostics, it's the pace of controlled product rollouts (F&A still described as 'controlled' and 'broadening' two quarters after promising 'full volume ramp in the second half') and management's own caution on wellness-visit recovery. The most revealing moment came when management was asked about the multi-cue platform directly and offered only: 'we're very comfortable with our capacity from a commercial standpoint', no name, no date, no TAM, on a product teased quarters ago. My view changes if the August 13 Investor Day delivers a hard multi-cue timeline and TAM, or if Q3 installed base growth reaccelerates back above 11%; absent that, this is a well-executed quarter wrapped in slightly thinner conviction than the beat-and-raise headline suggests.